Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cereblon enhancer methylation and IMiD resistance in multiple myeloma

11 Jun 2021

Abstract excerpt

Cereblon is the direct binding target of the immunomodulatory drugs (IMiDs) that are commonly used to treat multiple myeloma (MM), the second most frequent hematologic malignancy. Patients respond well to initial treatment with IMiDs, but virtually all patients develop drug resistance over time, and the underlying mechanisms are poorly understood. We identified an as yet undescribed DNA hypermethylation in an...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Histone Deacetylase Inhibitors Research
Share to Multiple Myeloma Research and Treatments
Share to Protein Degradation and Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 34115836
DOI: 10.1182/blood.2020010452

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cereblon enhancer methylation and IMiD resistance in multiple myelomaPMID 34115836Read ↗

Tumor and microenvironmental mechanisms of resistance to immunomodulatory drugs in multiple myelomaSemantic proximity Read ↗

Expression, mutation, and methylation of cereblon-pathway genes at pre- and post-lenalidomide treatment in multiple myeloma.Semantic proximity Read ↗

Dual inhibition of DNMTs and EZH2 can overcome both intrinsic and acquired resistance of myeloma cells to IMiDs in a cereblon‐independent mannerSemantic proximity Read ↗

Identification of cereblon-binding proteins and relationship with response and survival after IMiDs in multiple myelomaSemantic proximity Read ↗

IMiD Resistance in Multiple Myeloma: Current Understanding of the Underpinning Biology and Clinical ImpactSemantic proximity Read ↗

Cereblon loss and up-regulation of c-Myc are associated with lenalidomide resistance in multiple myeloma patientsSemantic proximity Read ↗

The Role of Epigenetics in the Development and Progression of Multiple MyelomaSemantic proximity Read ↗

Aberrant DNA methylation in multiple myeloma: A major obstacle or an opportunity?Semantic proximity Read ↗

Development of Gene Expression–Based Score to Predict Sensitivity of Multiple Myeloma Cells to DNA Methylation InhibitorsSemantic proximity Read ↗

Dynamic super-enhancer core regulatory circuits and epigenetic landscapes drive malignant progression and refractory disease in multiple myelomaSemantic proximity Read ↗

Cereblon and IRF4 Variants Affect Risk and Response to Treatment in Multiple Myeloma.Semantic proximity Read ↗

Multiple cereblon genetic changes are associated with acquired resistance to lenalidomide or pomalidomide in multiple myeloma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.